A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4

被引：0
|
作者：
Tian, Meijie
Jia, Katrina
Wu, Jerry T.
Wei, Jun S.
Cheuk, Adam T.
Zhang, Zhongmei
Pope, Eleanor G.
Shor, Boris
Tumey, L. Nathan
Khan, Javed
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB042
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase I study of fibroblast growth factor receptor 2 antibody-drug conjugate (FGFR2-ADC) BAY 1187982 in patients with advanced cancer
    Kim, Sung-Bae
    Meric-Bernstam, Funda
    Berlin, Jordan
    Wittemer-Rump, Sabine
    Osada, Motonobu
    Valencia, Ray
    Babich, Aleksei
    Liu, Rong
    Hwang, Andy
    Tanigawa, Takahiko
    Reetz, Frank
    Laurent, Dirk
    Kalyan, Aparna
    CANCER RESEARCH, 2017, 77
  • [32] Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate
    Yu, Shan
    Pearson, Aaron D.
    Lim, Reyna K. V.
    Rodgers, David T.
    Li, Sijia
    Parker, Holly B.
    Weglarz, Meredith
    Hampton, Eric N.
    Bollong, Michael J.
    Shen, Jiayin
    Zambaldo, Claudio
    Wang, Danling
    Woods, Ashley K.
    Wright, Timothy M.
    Schultz, Peter G.
    Kazane, Stephanie A.
    Young, Travis S.
    Tremblay, Matthew S.
    MOLECULAR THERAPY, 2016, 24 (12) : 2078 - 2089
  • [33] IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors
    Ab, Olga
    Whiteman, Kathleen R.
    Bartle, Laura M.
    Sun, Xiuxia
    Singh, Rajeeva
    Tavares, Daniel
    LaBelle, Alyssa
    Payne, Gillian
    Lutz, Robert J.
    Pinkas, Jan
    Goldmacher, Victor S.
    Chittenden, Thomas
    Lambert, John M.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07) : 1605 - 1613
  • [34] A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer
    Kollmannsberger, Christian
    Britten, Carolyn D.
    Olszanski, Anthony J.
    Walker, Joan Andrews
    Zang, Wei
    Willard, Melinda D.
    Radtke, David B.
    Farrington, Daphne L.
    Bell-McGuinn, Katherine M.
    Patnaik, Amita
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1613 - 1623
  • [35] Development of anti-5T4 antibody-drug conjugates, ZVO5-ADCs for targeted cancer therapy in different type of cancers
    Li, Zhaohui
    Xie, Zhangming
    Zhang, Qian
    Fang, Jie
    Wu, Liqin
    Fang, Hedi
    Zhang, Hong
    Zhu, Tong
    Chen, Gang
    Miao, David
    Cao, Sheldon
    CANCER RESEARCH, 2016, 76
  • [36] Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors
    Mignard, Caroline
    Durix, Coralie
    Rybinski, Katherine
    Cheng, Xin
    Furuuchi, Keiji
    Albone, Earl
    Uenaka, Toshimitsu
    de Boisferon, Marc Hillairet
    CANCER RESEARCH, 2018, 78 (13)
  • [37] RADIOIMMUNOTHERAPY OF AT-211-LABELED ANTI-FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4) ANTIBODY IS A PROMISING THERAPY FOR PERITONEAL DISSEMINATION OF GASTRIC CANCER: IN IMMUNOCOMPETENT MICE STUDY
    Kuge, Komei
    Masuda, Hiroki
    Du, Wanying
    Yasuda, Tomohiko
    Sugiyama, Akira
    Haba, Hiromitsu
    Tatsumi, Toshifumi
    Akimitsu, Nobuyoshi
    Kumakura, Yoshitaka
    Yoshida, Hiroshi
    Seto, Yasuyuki
    Wada, Youichiro
    Nomura, Sachiyo
    GASTROENTEROLOGY, 2024, 166 (05) : S392 - S392
  • [38] Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers
    Zammarchi, Francesca
    Havenith, Karin
    de Haan, Lolke
    Kirby, Ian
    Janghra, Narinder
    Gil, Veronica
    Alves, Pedro
    Zaitseva, Kristina
    Kerr, Meghann
    Leatherdale, Ben
    Patel, Afroze
    Thoelke, Marie
    Huang, Shiran
    Hartley, John A.
    van Berkel, Patrick H.
    CANCER RESEARCH, 2023, 83 (07)
  • [39] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
    Challita-Eid, Pia M.
    Satpayev, Daulet
    Yang, Peng
    An, Zili
    Morrison, Karen
    Shostak, Yuriy
    Raitano, Arthur
    Nadell, Rossana
    Liu, Wendy
    Lortie, Dawn Ratay
    Capo, Linnette
    Verlinsky, Alla
    Leavitt, Monica
    Malik, Faisal
    Avina, Hector
    Guevara, Claudia I.
    Dinh, Nick
    Karki, Sher
    Anand, Banmeet S.
    Pereira, Daniel S.
    Joseph, Ingrid B. J.
    Donate, Fernando
    Morrison, Kendall
    Stover, David R.
    CANCER RESEARCH, 2016, 76 (10) : 3003 - 3013
  • [40] Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers
    Zhou, Wei
    Fang, Peng
    Yu, Dongan
    Ren, Hongyuan
    You, Meng
    Yin, Long
    Mei, Fei
    Zhu, Huikai
    Wang, Zhenzhen
    Xu, Hui
    Cao, Yuxia
    Sun, Xiaowei
    Xu, Xiaohong
    Bi, Jianjun
    Wang, Jin
    Ma, Lanping
    Wang, Xin
    Chen, Lin
    Zhang, Yongliang
    Cen, Xiaowei
    Zhu, Xi
    Lou, Liguang
    Liu, Datao
    Tan, Xiaoding
    Yang, Jinliang
    Meng, Tao
    Shen, Jingkang
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (08) : 913 - 925
12345